Artificial intelligence medications may reach markets in 2030

It is likely that the first developed drugs with artificial intelligence techniques are likely to reach the commercial markets by the end of the contract, according to the head of an emerging company specialized in discovering medications based on artificial intelligence techniques.

“I will be surprised if we do not see it during the next five or six years,” said Alex Zafuronkov, CEO of “Insilico Medicine”, in an interview with Bloomberg TV. He added: “I hope to be the first to achieve this achievement. We are working on more than 40 internal programs, but no one knows what will happen.”

The pharmaceutical industry has always promoted the capabilities of artificial intelligence in accelerating the pace of research and development and reducing its costs, although none of them is approved so far. Takeda Pharmaceutical, the final stages of clinical trials for psoriasis treatment, were chosen through artificial intelligence, as his data is expected this year.

The role of artificial intelligence in the development of medicines
Although most companies are currently using artificial intelligence, what distinguishes the company “Insyliko” is its integration of technology at each stage of the drug development, starting with the status of targeting hypotheses, to improving the pharmaceutical composition to produce ready -made treatments for human experiments, according to Zaporenkov.

The operations of “Ecseliko” are spread through the United States, China, the Middle East and Canada, and the company has recently re -submitted an application on the Hong Kong Stock Exchange, after completing a special financing round that raised its evaluation to more than one billion dollars.